FDA expedites review of BioMarin's rare-disease drug Vimizim

05/31/2013 | RTT News

The FDA has accepted BioMarin Pharmaceutical's biologics license application for Vimizim, or BMN-110, elosulfase alfa, an experimental treatment for Mucopolysaccharidosis type IVA, also known as Morquio A Syndrome. The enzyme replacement therapy was granted a priority-review status.

View Full Article in:

RTT News

Published in Brief:

SmartBrief Job Listings for Health Care